← Back
Data updated: Mar 10, 2026
CMP DEV LLC
CardiovascularMetabolicRespiratory
CMP DEV LLC is a pharmaceutical company focused on Cardiovascular, Metabolic, Respiratory. Key products include ATORVALIQ.
2017
Since
7
Drugs
-
Trials
9
Approved (2yr)
Key Drugs
ATORVALIQ
atorvastatin calcium
HMG-CoA reductase 11 indications · 2023
NORLIQVA
amlodipine besylate
Calcium channel 4 indications · 2022
CAROSPIR
spironolactone
Aldosterone Receptor 3 indications · 2017
QUIOFIC
folic acid
2 indications · 2026
POTASSIUM PHOSPHATES
potassium phosphate, dibasic
1 indications · 2019
Recent Activity
NORLIQVA 2026-02-02
Labeling
QUIOFIC 2026-01-26
Type 3 - New Dosage Form
POTASSIUM PHOSPHATES 2025-09-11
POTASSIUM PHOSPHATES 2025-02-19
Manufacturing (CMC)
POTASSIUM PHOSPHATES 2025-01-30
Manufacturing (CMC)
POTASSIUM PHOSPHATES 2025-01-24
POTASSIUM PHOSPHATES 2024-08-30
Manufacturing (CMC)
POTASSIUM PHOSPHATES 2024-07-11
ATORVALIQ 2024-04-23
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 67%
4 drugs
Metabolic 17%
1 drugs
Respiratory 17%
1 drugs
Pipeline Strength Pro
Loading...